Investigational drugs for visceral leishmaniasis

Bibliography

• Control of the Leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. 22-26 March, 2010. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf
   Google Scholar
• Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995;13(3):505-23
   PubMed Web of Science ®Google Scholar
• Pearson RD, deQueiroz Sousa A. Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF, editor. Tropical infectious diseases: principles, pathogens and practice. Churchill Livingstone; Philadelphia: 1999. p. 797-813
   Google Scholar
• Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003;3(2):87-98
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kumar K. Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann Trop Med Parasitol 1992;86(4):355-9
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7(9):581-96
   PubMed Web of Science ®Google Scholar
• Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7(5):e35671
   Google Scholar
• Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10(2):298-319
   PubMed Web of Science ®Google Scholar
• Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003;97(Suppl 1):3-15
   PubMed Web of Science ®Google Scholar
• Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008;21(2):334-59; table of contents
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362(6):504-12
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011;377(9764):477-86
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother 2013;14(1):53-63
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000;31(4):1104-7
   PubMed Web of Science ®Google Scholar
• Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003;97(3):350-4
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012;55(4):543-50
   PubMed Web of Science ®Google Scholar
• Winkelmann E, Raether W. New chemotherapeutically active nitroimidazoles. Curr Chemother Infect Dis Proc Int Congr Chemother 11th 1980;2:969-70
   Google Scholar
• Raether W, Seidenath H. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Ann Trop Med Parasitol 1983;77(1):13-26
   PubMed Web of Science ®Google Scholar
• Jennings FW, Urquhart GM. The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z Parasitenkd 1983;69(5):577-81
   PubMed Web of Science ®Google Scholar
• Torreele E, Tweats D, Kaiser M, et al. Fexinidazole – a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 2010;4(12):e923
   PubMed Web of Science ®Google Scholar
• Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008;105(13):5022-7
   PubMed Web of Science ®Google Scholar
• Sokolova AY, Wyllie S, Patterson S, et al. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother 2010;54(7):2893-900
   PubMed Web of Science ®Google Scholar
• Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 2011;286(15):13088-95
   PubMed Web of Science ®Google Scholar
• Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003;90(Suppl 1):S19-39
   PubMedGoogle Scholar
• Wyllie S, Patterson S, Stojanovski L, et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 2012;4(119):119re1
   PubMed Web of Science ®Google Scholar
• Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient SCID mice. Antimicrob Agents Chemother 2001;45(6):1872-5
   PubMed Web of Science ®Google Scholar
• Tweats D, Bourdin Trunz B, Torreele E. Genotoxicity profile of fexinidazole – a drug candidate in clinical development for human African trypanomiasis (sleeping sickness). Mutagenesis 2012;27(5):523-32
   PubMed Web of Science ®Google Scholar
• Human African trypanosomiasis: first in man clinical trial of a new medicinal product, the fexinidazole. 9th March, 2011 Available from: http://clinicaltrials.gov/show/NCT00982904 [Accessed on 21st February 2014]
   Google Scholar
• Multiple dose study to evaluate security, tolerance and pharmacokinetic of fexinidazole (Drug Candidate for Human African Trypanosomiasis) administered with a loading dose and with food. February 10, 2012 Available from: http://clinicaltrials.gov/show/NCT01483170 [Accessed on 21st February, 2014]
   Google Scholar
• Fexinidazole (1200mg) bioavailability under different food intake conditions. Available from: http://clinicaltrials.gov/ct2/show/NCT01340157 [Accessed on 21st February, 2014]
   Google Scholar
• Pivotal study of fexinidazole for human African trypanosomiasis in stage 2. Available from: http://clinicaltrials.gov/show/NCT01685827 [Accessed on 21st February, 2014]
   Google Scholar
• Trial to determine efficacy of fexinidazole in visceral leihmaniasis patients in Sudan. Available from: http://clinicaltrials.gov/show/NCT01980199 [Accessed on 21st February, 2014]
   Google Scholar
• Barry CEIII, Boshoff HI, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004;10(26):3239-62
   PubMed Web of Science ®Google Scholar
• Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009;53(9):3720-5
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52(4):1522-4
   PubMed Web of Science ®Google Scholar
• Patterson S, Wyllie S, Stojanovski L, et al. The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis. Antimicrob Agents Chemother 2013;57(10):4699-706
   PubMed Web of Science ®Google Scholar
• Gurumurthy M, Mukherjee T, Dowd CS, et al. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J 2012;279(1):113-25
   PubMed Web of Science ®Google Scholar
• Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008;322(5906):1392-5
   PubMed Web of Science ®Google Scholar
• Manjunatha UH, Boshoff H, Dowd CS, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006;103(2):431-6
   PubMed Web of Science ®Google Scholar
• Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405(6789):962-6
   PubMed Web of Science ®Google Scholar
• Winter H, Ginsberg A, Egizi E, et al. Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. Antimicrob Agents Chemother 2013;57(11):5516-20
   PubMed Web of Science ®Google Scholar
• Winter H, Egizi E, Erondu N, et al. Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects. Antimicrob Agents Chemother 2013;57(8):3699-703
   PubMed Web of Science ®Google Scholar
• Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother 2009;53(9):3726-33
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380(9846):986-93
   PubMed Web of Science ®Google Scholar
• Pham TT, Loiseau PM, Barratt G. Strategies for the design of orally bioavailable antileishmanial treatments. Int J Pharm 2013;454(1):539-52
   PubMedGoogle Scholar
• Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47(1):3-19
   PubMed Web of Science ®Google Scholar
• Manandhar KD, Yadav TP, Prajapati VK, et al. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother 2008;62(2):376-80
   PubMed Web of Science ®Google Scholar
• Asthana S, Jaiswal AK, Gupta PK, et al. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother 2013;57(4):1714-22
   PubMed Web of Science ®Google Scholar
• Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine 2008;4(3):183-200
   PubMed Web of Science ®Google Scholar
• Prajapati VK, Awasthi K, Gautam S, et al. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother 2011;66(4):874-9
   PubMed Web of Science ®Google Scholar
• Georgakilas V, Kordatos K, Prato M, et al. Organic functionalization of carbon nanotubes. J Am Chem Soc 2002;124(5):760-1
   PubMed Web of Science ®Google Scholar
• Prajapati Vk, Yadav TP, Rai M, et al. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis 2012;205(2):333-6
   PubMed Web of Science ®Google Scholar
• Wasan EK, Bartlett K, Gershkovich P, et al. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 2009;372(1-2):76-84
   PubMed Web of Science ®Google Scholar
• Wasan KM, Wasan EK, Gershkovich P, et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 2009;200(3):357-60
   PubMed Web of Science ®Google Scholar
• Wasan EK, Gershkovich P, Zhao J, et al. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. PLoS Negl Trop Dis 2010;4(12):e913
   PubMed Web of Science ®Google Scholar
• Sivak O, Gershkovich P, Lin M, et al. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids Health Dis 2011;10:135
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Gershkovich P, Sivak O, et al. Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats. Drug Dev Ind Pharm 2013;39(9):1277-83
   PubMed Web of Science ®Google Scholar
• Gupta PK, Jaiswal AK, Kumar V, et al. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation. Mol Pharm 2014; Epub ahead of print
   Google Scholar
• Les KA, Balan S, Choi J, et al. Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases. Polym Chem 2014;5:1037-48
   Google Scholar
• Nicoletti S, Seifert K, Gilbert IH. N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents 2009;33(5):441-8
   PubMed Web of Science ®Google Scholar
• Singodia D, Verma A, Verma RK, Mishra PR. Investigations into an alternate approach to target mannose receptors on macrophages using 4-sulfated N-acetyl galactosamine more efficiently in comparison with mannose-decorated liposomes: an application in drug delivery. Nanomedicine 2012;8(4):468-77
   PubMed Web of Science ®Google Scholar
• Alsaadi M, Italia JL, Mullen AB, et al. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. J Control Release 2012;160(3):685-91
   PubMed Web of Science ®Google Scholar
• Sanchez-Brunete JA, Dea MA, Rama S, et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004;48(9):3246-52
   PubMed Web of Science ®Google Scholar
• Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res 2009;26(12):2588-98
   PubMed Web of Science ®Google Scholar
• Nahar M, Dubey V, Mishra D, et al. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target 2010;18(2):93-105
   PubMed Web of Science ®Google Scholar
• Pruthi J, Mehra NK, Jain NK. Macrophages targeting of amphotericin B through mannosylated multiwalled carbon nanotubes. J Drug Target 2012;20(7):593-604
   PubMed Web of Science ®Google Scholar
• Chakrabarti G, Basu A, Manna PP, et al. Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis. J Antimicrob Chemother 1999;43(3):359-66
   PubMed Web of Science ®Google Scholar
• Galvao LO, Moreira Junior S, Medeiros Junior P, et al. Therapeutic trial in experimental tegumentary leishmaniasis caused by Leishmania (Leishmania) amazonensis. A comparative study between mefloquine and aminosidine. Rev Soc Bras Med Trop 2000;33(4):377-82
   PubMedGoogle Scholar
• Nakayama H, Loiseau PM, Bories C, et al. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 2005;49(12):4950-6
   PubMed Web of Science ®Google Scholar
• Sherwood JA, Gachihi GS, Muigai RK, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994;19(6):1034-9
   PubMed Web of Science ®Google Scholar
• Mishra BB, Singh RK, Srivastava A, et al. Fighting against Leishmaniasis: search of alkaloids as future true potential anti-Leishmanial agents. Mini Rev Med Chem 2009;9(1):107-23
   PubMed Web of Science ®Google Scholar
• Sahu NP, Pal C, Mandal NB, et al. Synthesis of a novel quinoline derivative, 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide – a potential antileishmanial agent. Bioorg Med Chem 2002;10(6):1687-93
   PubMed Web of Science ®Google Scholar
• Fournet A, Barrios AA, Munoz V, et al. 2-substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob Agents Chemother 1993;37(4):859-63
   PubMed Web of Science ®Google Scholar
• Fournet A, Gantier JC, Gautheret A, et al. The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. J Antimicrob Chemother 1994;33(3):537-44
   PubMed Web of Science ®Google Scholar
• Vieira NC, Herrenknecht C, Vacus J, et al. Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomed Pharmacother 2008;62(10):684-9
   PubMed Web of Science ®Google Scholar
• Campos Vieira N, Vacus J, Fournet A, et al. Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model. Parasite 2011;18(4):333-6
   PubMed Web of Science ®Google Scholar
• Gopinath VS, Pinjari J, Dere RT, et al. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents. Eur J Med Chem 2013;69:527-36
   PubMed Web of Science ®Google Scholar
• Fakhfakh MA, Fournet A, Prina E, et al. Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections. Bioorg Med Chem 2003;11(23):5013-23
   PubMed Web of Science ®Google Scholar
• Palit P, Hazra A, Maity A, et al. Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2012;56(1):432-45
   PubMed Web of Science ®Google Scholar
• Beveridge E, Goodwin LG, Walls LP. A new series of leishmanicides. Nature 1958;182(4631):316-17
   PubMed Web of Science ®Google Scholar
• Kinnamon KE, Steck EA, Loizeaux PS, et al. The antileishmanial activity of lepidines. Am J Trop Med Hyg 1978;27(4):751-7
   PubMed Web of Science ®Google Scholar
• Theoharides AD, Ashmore RW, Shipley LA. Identification and quantification of human urinary metabolites of a candidate 8-aminoquinoline antileishmanial drug WR-6026. Fed Proc Fed Am Soc Exp Biol 1987;46:865
   Google Scholar
• Theoharides AD, Chung H, Velazquez H. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochem Pharmacol 1985;34(2):181-8
   PubMed Web of Science ®Google Scholar
• Yeates C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Investig Drugs 2002;3(10):1446-52
   PubMedGoogle Scholar
• Sundar S, Sinha PK, Dixon SA, et al. Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India. Am J Trop Med Hyg 2011;84(6):892-900
   PubMed Web of Science ®Google Scholar
• Dietze R, Carvalho SF, Valli LC, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001;65(6):685-9
   PubMed Web of Science ®Google Scholar
• Jha TK, Sundar S, Thakur CP, et al. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005;73(6):1005-11
   PubMed Web of Science ®Google Scholar
• Wasunna MK, Rashid JR, Mbui J, et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005;73(5):871-6
   PubMed Web of Science ®Google Scholar
• Bories C, Cojean S, Huteau F, Loiseau PM. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomed Pharmacother 2008;62(3):164-7
   PubMed Web of Science ®Google Scholar
• Loiseau PM, Cojean S, Schrevel J. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite 2011;18(2):115-19
   PubMed Web of Science ®Google Scholar
• Fournet A, Angelo A, Munoz V, et al. Biological and chemical studies of Pera benensis, a Bolivian plant used in folk medicine as a treatment of cutaneous leishmaniasis. J Ethnopharmacol 1992;37(2):159-64
   PubMed Web of Science ®Google Scholar
• Croft SL, Hogg J, Gutteridge WE, et al. The activity of hydroxynaphthoquinones against Leishmania donovani. J Antimicrob Chemother 1992;30(6):827-32
   PubMed Web of Science ®Google Scholar
• Mantyla A, Rautio J, Nevalainen T, et al. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. Bioorg Med Chem 2004;12(13):3497-502
   PubMed Web of Science ®Google Scholar
• Garnier T, Mantyla A, Jarvinen T, et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother 2007;60(4):802-10
   PubMed Web of Science ®Google Scholar
• Reimao JQ, Colombo FA, Pereira-Chioccola VL, Tempone AG. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. Exp Parasitol 2012;130(3):195-9
   PubMed Web of Science ®Google Scholar
• Mishra BB, Gour JK, Kishore N, et al. An antileishmanial prenyloxy-naphthoquinone from roots of Plumbago zeylanica. Nat Prod Res 2012;27(4-5):480-5
   PubMed Web of Science ®Google Scholar
• Lezama-Davila CM, Isaac-Marquez AP, Kapadia G, et al. Leishmanicidal activity of two naphthoquinones against Leishmania donovani. Biol Pharm Bull 2012;35(10):1761-4
   PubMed Web of Science ®Google Scholar
• Hazra S, Ghosh S, Das Sarma M, et al. Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani. Exp Parasitol 2013;135(2):407-13
   PubMed Web of Science ®Google Scholar
• Sett R, Basu N, Ghosh AK, Das PK. Potential of doxorubicin as an antileishmanial agent. J Parasitol 1992;78(2):350-4
   PubMed Web of Science ®Google Scholar
• Sett R, Sarkar K, Das PK. Macrophage-directed delivery of doxorubicin conjugated to neoglycoprotein using leishmaniasis as the model disease. J Infect Dis 1993;168(4):994-9
   PubMed Web of Science ®Google Scholar
• Basu N, Kole L, Ghosh A, Das PK. Expression and characterization of a parasite-specific antigen on macrophages after infection with Leishmania donovani. Mol Cell Biochem 1994;132(1):1-6
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Das L, Kole L, et al. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. J Infect Dis 2004;189(6):1024-34
   PubMed Web of Science ®Google Scholar
• Gupta GK, Kansal S, Misra P, et al. Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages. AAPS PharmSciTech 2009;10(4):1343-7
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Gupta S, Dwivedi AK, et al. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J Microencapsul 2011;28(4):301-10
   PubMed Web of Science ®Google Scholar
• Kansal S, Tandon R, Dwivedi P, et al. Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. J Antimicrob Chemother 2012;67(11):2650-60
   PubMed Web of Science ®Google Scholar
• Kansal S, Tandon R, Verma PR, et al. Development of doxorubicin loaded novel core shell structured nanocapsules for the intervention of visceral leishmaniasis. J Microencapsul 2013;30(5):441-50
   PubMed Web of Science ®Google Scholar
• Chapman WLJr, Hanson WL, Alving CR, Hendricks LD. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res 1984;45(5):1028-30
   PubMed Web of Science ®Google Scholar
• Banerjee G, Nandi G, Mahato SB, et al. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 1996;38(1):145-50
   PubMed Web of Science ®Google Scholar
• Nieto J, Alvar J, Mullen AB, et al. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother 2003;47(9):2781-7
   PubMed Web of Science ®Google Scholar
• Paul M, Durand R, Boulard Y, et al. Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 1998;5(6):481-90
   PubMed Web of Science ®Google Scholar
• Menez C, Legrand P, Rosilio V, et al. Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B. Mol Pharm 2007;4(2):281-8
   PubMedGoogle Scholar
• Menez C, Buyse M, Besnard M, et al. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob Agents Chemother 2006;50(11):3793-800
   PubMed Web of Science ®Google Scholar
• Menez C, Buyse M, Chacun H, et al. Modulation of intestinal barrier properties by miltefosine. Biochem Pharmacol 2006;71(4):486-96
   PubMed Web of Science ®Google Scholar
• Nwaka S, Ramirez B, Brun R, et al. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 2009;3(8):e440
   PubMed Web of Science ®Google Scholar
• Singh N, Mishra BB, Bajpai S, et al. Natural product based leads to fight against leishmaniasis. Bioorg Med Chem 2014;22(1):18-45
   PubMed Web of Science ®Google Scholar
• Mishra BB, Kale RR, Singh RK, Tiwari VK. Alkaloids: future prospective to combat leishmaniasis. Fitoterapia 2009;80(2):81-90
   PubMed Web of Science ®Google Scholar
• Salem MM, Werbovetz KA. Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis. Curr Med Chem 2006;13(21):2571-98
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Mukherjee B, Mukhopadhyay R, et al. Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection. PLoS Negl Trop Dis 2012;6(12):e1987
   PubMed Web of Science ®Google Scholar
• Palit P, Ali N. Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmania donovani. J Antimicrob Chemother 2008;61(5):1120-4
   PubMed Web of Science ®Google Scholar
• Suryawanshi SN, Tiwari A, Kumar S, et al. Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents. Bioorg Med Chem Lett 2013;23(10):2925-8
   PubMed Web of Science ®Google Scholar
• Sharma M, Chauhan K, Shivahare R, et al. Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents. J Med Chem 2013;56(11):4374-92
   PubMed Web of Science ®Google Scholar
• Kyriazis JD, Aligiannis N, Polychronopoulos P, et al. Leishmanicidal activity assessment of olive tree extracts. Phytomedicine 2012;20(3-4):275-81
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Ghosh P, De T, et al. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity. Exp Parasitol 2013;135(1):126-33
   PubMed Web of Science ®Google Scholar
• Khaliq T, Misra P, Gupta S, et al. Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg Med Chem Lett 2009;19(9):2585-6
   PubMed Web of Science ®Google Scholar
• Maes L, Germonprez N, Quirijnen L, et al. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother 2004;48(6):2056-60
   PubMed Web of Science ®Google Scholar
• Germonprez N, Maes L, Van Puyvelde L, et al. In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives. J Med Chem 2005;48(1):32-7
   PubMed Web of Science ®Google Scholar
• Mittra B, Saha A, Chowdhury AR, et al. Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol Med 2000;6(6):527-41
   PubMed Web of Science ®Google Scholar
• Zhai L, Chen M, Blom J, et al. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 1999;43(6):793-803
   PubMed Web of Science ®Google Scholar
• Chen M, Christensen SB, Theander TG, Kharazmi A. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother 1994;38(6):1339-44
   PubMed Web of Science ®Google Scholar
• Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother 1999;44(6):791-4
   PubMed Web of Science ®Google Scholar